NCT05449535 - Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions

Healthy

Interventions

DRUG

JYB1904

Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.

DRUG

Omalizumab

Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.

DRUG

JYB1904 Placebo

Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.

Trial Locations (1)

310000

Shulan (Hangzhou) Hospital, Hangzhou